JP2024506999A - がんを処置するための組成物および方法 - Google Patents

がんを処置するための組成物および方法 Download PDF

Info

Publication number
JP2024506999A
JP2024506999A JP2023571436A JP2023571436A JP2024506999A JP 2024506999 A JP2024506999 A JP 2024506999A JP 2023571436 A JP2023571436 A JP 2023571436A JP 2023571436 A JP2023571436 A JP 2023571436A JP 2024506999 A JP2024506999 A JP 2024506999A
Authority
JP
Japan
Prior art keywords
cancer
methylene diamine
pharmaceutically acceptable
subject
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506999A5 (https=
Inventor
コン，ヤンピン
リウ，ジンホン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2024506999A publication Critical patent/JP2024506999A/ja
Publication of JP2024506999A5 publication Critical patent/JP2024506999A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023571436A 2021-02-02 2022-01-28 がんを処置するための組成物および方法 Pending JP2024506999A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144690P 2021-02-02 2021-02-02
US63/144,690 2021-02-02
PCT/US2022/014379 WO2022169690A1 (en) 2021-02-02 2022-01-28 Composition and methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2024506999A true JP2024506999A (ja) 2024-02-15
JP2024506999A5 JP2024506999A5 (https=) 2024-12-16

Family

ID=82742455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571436A Pending JP2024506999A (ja) 2021-02-02 2022-01-28 がんを処置するための組成物および方法

Country Status (8)

Country Link
US (1) US20240099992A1 (https=)
EP (1) EP4288040A4 (https=)
JP (1) JP2024506999A (https=)
KR (1) KR20230142733A (https=)
CN (1) CN117083061A (https=)
AU (1) AU2022218110A1 (https=)
CA (1) CA3209477A1 (https=)
WO (1) WO2022169690A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520761A (ja) * 2003-03-26 2006-09-14 レセプトイコン・アンパルトセルスカブ 薬物誘発性細胞毒性の予防のための化合物の使用
WO2007124250A2 (en) * 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
WO2007005644A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
AU2006275702A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
KR101380190B1 (ko) 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
JPWO2011002026A1 (ja) * 2009-06-30 2012-12-13 国立大学法人 熊本大学 アミロイド線維形成抑制剤及びその利用
RU2417999C2 (ru) * 2009-07-13 2011-05-10 Закрытое Акционерное Общество "Ива Фарм" БИЯДЕРНЫЕ КООРДИНАЦИОННЫЕ СОЕДИНЕНИЯ БИОЛОГИЧЕСКИ АКТИВНЫХ d-ЭЛЕМЕНТОВ С АЛИФАТИЧЕСКИМИ ТИОЛАМИ КАК СРЕДСТВА ПОВЫШЕНИЯ ЭФФЕКТИВНОСТИ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ
JP2011084541A (ja) * 2009-10-19 2011-04-28 Ltt Bio-Pharma Co Ltd 低分子薬物含有ナノ粒子
CA3064486C (en) 2017-04-20 2023-08-01 Geneheal Biotechnology Co., Ltd. Applications of spermidine and its derivatives
GB201804924D0 (en) * 2018-03-27 2018-05-09 Univ Oxford Innovation Ltd Radiolabelled compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520761A (ja) * 2003-03-26 2006-09-14 レセプトイコン・アンパルトセルスカブ 薬物誘発性細胞毒性の予防のための化合物の使用
WO2007124250A2 (en) * 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACTA CHEMICA SCANDINAVICA. SERIES B. ORGANIC CHEMISTRY AND BIOCHEMISTRY, vol. 32, no. 10, JPN6025039279, 1978, pages 759 - 764, ISSN: 0005837911 *
CARCINOGENESIS, vol. 21, no. 2, JPN6025039282, 2000, pages 195 - 203, ISSN: 0005837910 *
INTERNATIONAL JOURNAL OF CANCER, vol. 73, JPN6025039280, 1997, pages 113 - 116, ISSN: 0005694531 *

Also Published As

Publication number Publication date
KR20230142733A (ko) 2023-10-11
AU2022218110A1 (en) 2023-08-17
US20240099992A1 (en) 2024-03-28
CA3209477A1 (en) 2022-08-11
CN117083061A (zh) 2023-11-17
EP4288040A1 (en) 2023-12-13
EP4288040A4 (en) 2025-01-08
WO2022169690A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
Indap et al. Quercetin: Antitumor activity and pharmacological manipulations for increased therapeutic gains.
JP2025536179A (ja) 免疫チェックポイント遮断に基づく抗腫瘍医薬組成物及びその応用
RS61086B1 (sr) Farmaceutska kompozicija za tretiranje kancera koja sadrži metalnu so laktata
US20060275504A1 (en) Methods and compositions for augmenting cancer chemotherapeutic agents
TW201311234A (zh) 抗癌劑副作用改善用組成物
EP4424316A1 (en) Antitumor pharmaceutical composition comprising azvudine and chemotherapeutic agent
CN102688493B (zh) 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用
JP2024506999A (ja) がんを処置するための組成物および方法
US20250275938A1 (en) Compositions and methods for treatment of cancer
RS57256B1 (sr) Kombinovana terapija kancera jajnika
AU2019379782A1 (en) Combination of a Mcl-1 inhibitor and Midostaurin, uses and pharmaceutical compositions thereof
WO2016083992A1 (en) Titled extracts of cynara scolymus and uses thereof
HK40103289A (zh) 用於治疗癌症的组合物和方法
TW201904579A (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
KR101800129B1 (ko) 암의 예방 또는 치료용 약학적 조성물
KR20200121251A (ko) 항암제의 병용투여용 약학조성물
KR20110055833A (ko) 플라보노이드를 유효성분으로 하는 백혈병 치료용 조성물
KR102558989B1 (ko) 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도
EP3417864A1 (en) Immunosuppression weaning agent and use thereof
CN102727867A (zh) 一种抗肿瘤用药物组合物及应用、试剂盒及包装件
KR20250100273A (ko) 난소암 예방 또는 치료를 위한 데시타빈 및 벨로테칸의 병용 요법
JP2025177165A (ja) アントラサイクリン系抗癌剤により誘発される心毒性を予防及び／又は治療するための組成物
JP2026020821A (ja) 代謝抑制による抗腫瘍剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260413